Clinical Outcomes of COVID-19 Patients Treated with Convalescent Plasma or Remdesivir Alone and in Combination at a Community Hospital in California’s Central Valley

Authors

  • Regine Padilla San Joaquin General Hospital, French Camp, CA, USA
  • Jered Arquiette San Joaquin General Hospital, French Camp, CA, USA
  • Yvonne Mai University of the Pacific, Thomas J. Long School of Pharmacy, Stockton CA, USA
  • Gurinder Singh San Joaquin General Hospital, Department: Internal Medicine, French Camp, CA, USA
  • Kristine Galang San Joaquin General Hospital, Department of Internal Medicine, French Camp, CA, USA
  • Edward Liang University of the Pacific, Thomas J. Long School of Pharmacy, Stockton CA, USA

DOI:

https://doi.org/10.18433/jpps31969

Abstract

Purpose: The purpose of this study was to compare how treatment with convalescent plasma (CP) monotherapy, remdesivir (RDV) monotherapy, and combination therapy (CP + RDV) in patients with COVID-19 affected clinical outcomes. Methods: Patients with COVID-19 infection who were admitted to the hospital received CP, RDV, or combination of both. Mortality, discharge disposition, hospital length of stay (LOS), intensive care unit (ICU) LOS, and total ventilation days were compared between each treatment group and stratified by ABO blood group. An exploratory analysis identified risk factors for mortality. Adverse effects were also evaluated. Results: RDV monotherapy showed an increased chance of survival compared to combination therapy or CP monotherapy (p = 0.052). There were 15, 3, and 6 deaths in the CP, RDV, and combination therapy groups, respectively. The combination therapy group had the longest median ICU LOS (8, IQR 4.5-15.5, p = 0.220) and hospital LOS (11, IQR 7-15.5, p = 0.175). Age (p = 0.036), initial SOFA score (p = 0.013), and intubation (p = 0.005) were statistically significant predictors of mortality. Patients with type O blood had decreased ventilation days, ICU LOS, and total LOS. Thirteen treatment-related adverse events occurred. Conclusion: No significant differences in clinical outcomes were observed between patients treated with RDV, CP, or combination therapy. Elderly patients, those with a high initial SOFA score, and those who require intubation are at increased risk of mortality associated with COVID-19. Blood type did not affect clinical outcomes.

Downloads

Download data is not yet available.

Author Biographies

Regine Padilla, San Joaquin General Hospital, French Camp, CA, USA

Clinical Pharmacist 

Jered Arquiette, San Joaquin General Hospital, French Camp, CA, USA

Clinical Pharmacist

Yvonne Mai, University of the Pacific, Thomas J. Long School of Pharmacy, Stockton CA, USA

Assistant Professor of Pharmacy Practice

Gurinder Singh, San Joaquin General Hospital, Department: Internal Medicine, French Camp, CA, USA

Associate Program Director Internal Medicine Residency Program

Kristine Galang, San Joaquin General Hospital, Department of Internal Medicine, French Camp, CA, USA

Resident Physician

Edward Liang, University of the Pacific, Thomas J. Long School of Pharmacy, Stockton CA, USA

Pharm. D. student/pharmacy intern

Downloads

Published

2021-05-01

How to Cite

Padilla, R., Arquiette, J., Mai, Y., Singh, G., Galang, K., & Liang, E. (2021). Clinical Outcomes of COVID-19 Patients Treated with Convalescent Plasma or Remdesivir Alone and in Combination at a Community Hospital in California’s Central Valley. Journal of Pharmacy &Amp; Pharmaceutical Sciences, 24, 210–219. https://doi.org/10.18433/jpps31969

Issue

Section

Clinical Pharmacology and Therapeutics